keyword
Keywords ace inhibitor cardiorenal prot...

ace inhibitor cardiorenal protection

https://read.qxmd.com/read/22487948/effects-of-combined-endothelin-a-receptor-and-renin-angiotensin-system-blockade-on-the-course-of-end-organ-damage-in-5-6-nephrectomized-ren-2-hypertensive-rats
#21
JOURNAL ARTICLE
Ivana Vaněčková, Petr Kujal, Zuzana Husková, Zdeňka Vaňourková, Zdenka Vernerová, Věra Certíková Chábová, Petra Skaroupková, Herbert J Kramer, Vladimír Tesař, Luděk Červenka
Our previous studies in rats with ablation nephrectomy have shown similar cardiorenal protective effects of renin-angiotensin system (RAS)-dependent treatment (combination of angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker) and RAS-independent treatment (combination of α- and β-adrenoreceptor antagonist and diuretics). Moreover, selective blockade of endothelin (ET) receptor type A (ET(A)) improved survival rate and attenuated hypertension and organ damage in Ren-2 transgenic rats...
2012: Kidney & Blood Pressure Research
https://read.qxmd.com/read/22051431/reducing-cardiorenal-risk-through-combination-therapy-with-a-direct-renin-inhibitor
#22
REVIEW
Anjay Rastogi, Mohamad Rashid, Richard F Wright
Interruption of the renin-angiotensin-aldosterone system (RAAS) cascade with angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or more recently direct renin inhibitors (DRIs) is a safe and effective antihypertensive strategy that is in routine clinical use. The clinical utility of these agents in cardiorenal end-organ protection is increasingly being recognized. Although both ACE inhibitors and ARBs demonstrate substantial benefit in patients with cardiovascular and/or renal disease, considerable evidence indicates that they only partially suppress the RAAS pathway due to feedback upregulation of plasma renin activity...
November 2011: Journal of Clinical Hypertension
https://read.qxmd.com/read/21755729/ramipril-and-risk-of-hyperkalemia-in-chronic-hemodialysis-patients
#23
JOURNAL ARTICLE
Mirna Krajina-Andricević, Lada Zibar, Karin Juras, Sanda Goll-Barić, Jerko Barbić
Angiotensin converting enzyme (ACE) inhibitors provide well known cardiorenal-protective benefits added to antihypertensive effects in chronic renal disease. These agents are underused in management of patients receiving hemodialysis (HD) because of common concern of hyperkalemia. However, few studies have investigated effect of renin angiotensin aldosterone system (RAAS) blockade on serum potassium in hemodialysis patients. We assessed the safety of ramipril in patients on maintenance HD. We enrolled 28 adult end stage renal disease (ESRD) patients treated by maintenance HD and prescribed them ramipril in doses of 1...
June 2011: Collegium Antropologicum
https://read.qxmd.com/read/21570538/-advantages-and-limitations-of-renin-inhibition-with-aliskiren
#24
REVIEW
M Azizi, M Frank, O Steichen, A Blanchard
In the current context of renin-angiotensin-aldosterone system (RAAS) blockade, angiotensin (Ang) converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), or their combination, have proved to be effective in providing cardiovascular and renal protection. However, renin inhibition has long been recognized as the preferred site for blockade of the RAAS because renin represents the first, highly-regulated and rate-limiting step of the system. Up to now, the first orally active renin inhibitors initially tested in humans did not meet the necessary all the criteria (specificity, potency, and pharmacokinetic profile) to become clinically useful drugs...
May 2011: Annales Pharmaceutiques Françaises
https://read.qxmd.com/read/21266915/synergism-of-telmisartan-and-amlodipine-on-blood-pressure-reduction-and-cardiorenal-protection-in-hypertensive-rats
#25
JOURNAL ARTICLE
Wei Liu, Wei Wang, Shu-Wei Song, Xiao-Fei Gu, Xiu-Juan Ma, Feng-Yun Su, Hao Zhang, Ai-Jun Liu, Ding-Feng Su
AIM: This study was designed to investigate the effects of telmisartan and amlodipine on reduction of blood pressure (BP), myocardial hypertrophy, and renal injury in hypertensive rats. METHOD: In acute experiments, the BP was measured in conscious freely moving rats. Spontaneously hypertensive rats were treated with intragastric administration of amlodipine (1, 2, 4 mg/kg), telmisartan (4, 8, 12, 16, 20 mg/kg), and their different combinations (4 + 4, 2 + 4, 4 + 8, 4 + 12, 1 + 4, 2 + 8, 4 + 16, 2 + 12, 1 + 8, 2 + 16, 2 + 20, 1 + 12, 1 + 16, 1 + 20 mg/kg)...
March 2011: Journal of Cardiovascular Pharmacology
https://read.qxmd.com/read/21119529/inhibition-of-mineralocorticoid-receptor-is-a-renoprotective-effect-of-the-3-hydroxy-3-methylglutaryl-coenzyme-a-reductase-inhibitor-pitavastatin
#26
JOURNAL ARTICLE
Xian Wu Cheng, Masafumi Kuzuya, Takeshi Sasaki, Aiko Inoue, Lina Hu, Haizhen Song, Zhe Huang, Ping Li, Kyosuke Takeshita, Akihiro Hirashiki, Kohji Sato, Guo-Ping Shi, Kenji Okumura, Toyoaki Murohara
OBJECTIVE: The mineralocorticoid receptor has been implicated in the pathogenesis of chronic cardiorenal disease. Statins improve renal remodeling and dysfunction in patients with proteinuric kidney diseases. We aimed to clarify the beneficial effects and mechanisms of action of statins in renal insufficiency. METHODS AND RESULTS: Dahl salt-sensitive rats fed a high-salt diet were treated from 12 to 20 weeks of age with vehicle, the reduced nicotinamide-adenine dinucleotide phosphate (NADPH) oxidase inhibitor apocynin, the synthetic cathepsin inhibitor E64d, or a low or high dosage of pitavastatin (1 or 3 mg/kg daily)...
March 2011: Journal of Hypertension
https://read.qxmd.com/read/20859542/aliskiren-and-valsartan-combination-therapy-for-the-management-of-hypertension
#27
REVIEW
Benjamin J Epstein
Combination therapy is necessary for most patients with hypertension, and agents that inhibit the renin-angiotensin-aldosterone system (RAAS) are mainstays in hypertension management, especially for patients at high cardiovascular and renal risk. Single blockade of the RAAS with an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) confers some cardiorenal protection; however, these agents do not extinguish the RAAS as evidenced by a reactive increase in plasma renin activity (PRA), a cardiovascular risk marker, and incomplete cardiorenal protection...
2010: Vascular Health and Risk Management
https://read.qxmd.com/read/19667536/when-hypertension-and-diabetes-coexist-strategies-for-cardiorenal-protection
#28
JOURNAL ARTICLE
M A Weber
Diabetes and hypertension frequently coexist, with effects potentially more detrimental than those of either condition alone. The combination increases the risk of both cardiovascular and renal morbidity and mortality. Antihypertensive drug therapy is of benefit to both nondiabetic and diabetic patients, but the greatest reduction in risk is seen in those with diabetes. Studies have shown the cardiorenal protective effects of therapy with angiotensin-converting enzyme inhibitors either alone or combined with calcium channel blockers...
October 2000: Postgraduate Medicine
https://read.qxmd.com/read/19491616/how-to-achieve-renal-protection-in-the-light-of-ontarget
#29
JOURNAL ARTICLE
Christos Chatzikyrkou, Jan Menne, Hermann Haller
Inhibition of the renin-angiotensin system (RAS) either with an angiotensin-converting enzyme inhibitor (ACEI) or an angiotensin receptor blocker (ARB) has been shown to be beneficial for cardiorenal protection. The combination of both is an exciting prospect and pathophysiologically plausible. The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) study provides evidence that dual blockade does not further reduce cardiovascular events or worsen renal outcomes. However, in patients with existing diabetic nephropathy, a trend towards a better outcome was observed...
June 2009: Journal of Hypertension. Supplement: Official Journal of the International Society of Hypertension
https://read.qxmd.com/read/19332965/are-renin-angiotensin-aldosterone-system-blockers-distinguishable-based-on-cardiovascular-and-renal-outcomes-in-nephropathy
#30
REVIEW
Rigas Kalaitzidis, George Bakris
Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) are the cornerstone of therapy for cardiovascular and renal disease because they protect against worsening outcomes in the respective target organs. Recent results from the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET) have confirmed that angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) confer similar cardioprotection and renoprotection, showing little to no benefit from the combination in cardiovascular disease...
March 2009: Postgraduate Medicine
https://read.qxmd.com/read/19166800/dual-blockade-of-the-renin-angiotensin-system-for-cardiorenal-protection-an-update
#31
REVIEW
Mustafa Arici, Yunus Erdem
The renin-angiotensin system (RAS) has an important role in hypertension and the continuum of cardiovascular and kidney disease. The inhibition of this system, either with an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin receptor blocker (ARB), has been shown to be beneficial for cardiorenal protection. Dual blockade with an ACE inhibitor and ARB may have additional benefits due to the more complete inhibition of the system. Most published trials, including recent large studies and meta-analyses, have reported either limited or no additional benefit...
February 2009: American Journal of Kidney Diseases
https://read.qxmd.com/read/18814762/-what-is-the-purpose-of-dual-or-triple-inhibition-of-the-renin-angiotensin-aldosterone-system
#32
REVIEW
D Legrand, J-M Krzesinski, A J Scheen
The blockade of the renin-angiotensin-aldosterone system (RAAS) is helpful in the management of arterial hypertension, congestive heart failure, post-myocardial infarction and diabetic nephropathy. Such blockade can be obtained with an angiotensin converting enzyme inhibitor, a specific antagonist of angiotensin II AT1 receptors, an aldosterone receptor antagonist and/or a direct inhibitor of renin such as aliskiren. Various studies have demonstrated that a dual or even triple RAAS inhibition may offer a better cardiorenal protection, in refractory congestive heart failure and in nephropathy with proteinuria...
August 27, 2008: Revue Médicale Suisse
https://read.qxmd.com/read/18575070/-how-i-treat-by-optimizing-the-blockade-of-the-renin-angiotensin-aldosterone-system
#33
JOURNAL ARTICLE
F Schleich, J M Krzesinski, L Piérard, A J Scheen
The blockade of the renin-angiotensin-aldosterone system (RAAS) has been shown to be useful, or even mandatory, in the management of arterial hypertension, congestive heart failure, post-myocardial infarction and nephropathy with albuminuria, due to diabetes or not. Such blockade can be obtained with an angiotensin converting enzyme inhibitor, a specific antagonist of angiotensin II AT1 receptors and/or recently a direct inhibitor of renin such as aliskiren. Various studies have demonstrated the advantage of optimising RAAS blockade in order to benefit of the best cardiorenal protection...
April 2008: Revue Médicale de Liège
https://read.qxmd.com/read/17255126/no-impact-of-hyperkalaemia-with-renin-angiotensin-system-blockades-in-maintenance-haemodialysis-patients
#34
COMPARATIVE STUDY
Sang-Woong Han, Young-Woong Won, Joo-Hark Yi, Ho-Jung Kim
BACKGROUND: Renin-angiotensin system (RAS) blockades, angiotensin converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) are well accepted for the cardiorenal-protective benefits added to antihypertensive effects in chronic kidney diseases (CKD), but associated with an increased risk of hyperkalaemia. However, few studies have investigated the effect of RAS blockades on serum potassium in dialysis patients. METHODS: Hyperkalaemia associated with RAS blockades by ACEI and/or ARB was evaluated in 69 patients on maintenance haemodialysis, who underwent a three-period crossover study in four groups (no exposure to RAS blockades, ACEI or ARB alone and ACEI plus ARB treatments), lasting one month in each period...
April 2007: Nephrology, Dialysis, Transplantation
https://read.qxmd.com/read/17161768/cardiorenal-protective-effects-of-year-long-antihypertensive-therapy-with-an-angiotensin-converting-enzyme-inhibitor-or-a-calcium-channel-blocker-in-spontaneously-hypertensive-rats
#35
COMPARATIVE STUDY
Toshihiko Ishimitsu, Takeaki Honda, Satoshi Ohta, Akira Akashiba, Toshiaki Takahashi, Tomoko Kameda, Masayoshi Yoshii, Junichi Minami, Masaki Takahashi, Hidehiko Ono, Hiroaki Matsuoka
BACKGROUND: The objective of this study was to evaluate the effect of year-long antihypertensive therapy with a calcium channel blocker and an angiotensin-converting enzyme (ACE) inhibitor on cardiac and renal injury. METHODS: Male 15-week-old spontaneously hypertensive rats (SHR) were given either a normal diet and normal drinking water (n = 10), a diet containing 0.05% nitrendipine (n = 10), or drinking water containing 50 mg/L of quinapril (n = 10). After 12 months of antihypertensive treatment, cardiovascular organ injuries were evaluated...
December 2006: American Journal of Hypertension
https://read.qxmd.com/read/16235511/adverse-interactions-of-rofecoxib-with-lisinopril-in-spontaneously-hypertensive-rats
#36
COMPARATIVE STUDY
Kiran Dubey, Dayal K Balani, C B Tripathi, Rajvir Singh, Rajiv Bajaj, K K Pillai
BACKGROUND: Hypertension and arthritis are frequent comorbidities. Nonsteroidal anti-inflammatory drugs (NSAIDs) are well known to produce hypertension or attenuate the effects of antihypertensive agents in a few patients. The influence of selective NSAIDs on blood pressure and the cardiovascular and renal effects of coxibs have still to be investigated. The purpose of this study was to test the hypothesis that rofecoxib interferes with antihypertensive activity and cardiorenal protective effects of lisinopril in spontaneously hypertensive rats (SHRs)...
2005: Clinical Toxicology
https://read.qxmd.com/read/15850764/optimizing-hypertension-and-vascular-health-focus-on-ethnicity
#37
REVIEW
Domenic Sica
Black individuals are at significantly higher risk for hypertension and its sequelae, including end-stage renal disease and congestive heart failure, compared with other ethnic groups. The reason for this increased risk is likely multifactorial: although genetic differences may play a partial role in the etiology and pathophysiology of hypertension in black patients, factors related to lifestyle, most notably high body mass index, appear to have a greater impact. The treatment approach to lowering blood pressure in blacks is the same as for other ethnic groups...
2004: Clinical Cornerstone
https://read.qxmd.com/read/15000298/cardiorenal-protective-effects-of-vasopeptidase-inhibition-with-omapatrilat-in-hypertensive-transgenic-mren-2-27-rats
#38
COMPARATIVE STUDY
Sally A Mifsud, Louise M Burrell, Eiji Kubota, Kassie Jaworski, Mark E Cooper, Jennifer L Wilkinson-Berka
Vasopeptidase inhibitors simultaneously inhibit both angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP). The aim of this study was to determine the cardiorenal effects of the vasopeptidase inhibitor omapatrilat in the transgenic m(Ren-2)27 rat which exhibits fulminant hypertension and severe organ pathology. At 6 weeks of age, male Ren-2 rats were randomized to receive no treatment (N = 10), the ACE inhibitor fosinopril 10 mg/kg/day (N = 10), or omapatrilat 10 mg/kg/day (N = 10) or 40 mg/kg/day (N = 10) by daily gavage for 24 weeks...
January 2004: Clinical and Experimental Hypertension: CHE
https://read.qxmd.com/read/12633543/accelerated-decline-and-prognostic-impact-of-renal-function-after-myocardial-infarction-and-the-benefits-of-ace-inhibition-the-cats-randomized-trial
#39
RANDOMIZED CONTROLLED TRIAL
H L Hillege, W H van Gilst, D J van Veldhuisen, G Navis, D E Grobbee, P A de Graeff, D de Zeeuw et al.
AIMS: Information regarding the cardiorenal axis in patients after a myocardial infarction (MI) is limited. We examined the change in renal function after a first MI, the protective effect of angiotensin converting enzyme (ACE) inhibition and the prognostic value of baseline renal function. METHODS AND RESULTS: The study population consisted of 298 patients with a first anterior wall MI who were randomized to the ACE inhibitor captopril or placebo after completion of streptokinase infusion...
March 2003: European Heart Journal
https://read.qxmd.com/read/11728259/cardiorenal-protection-in-diabetes
#40
REVIEW
T G Pickering
Diabetes is twice as common in hypertensive patients than in the general population, and is a major cause of cardiovascular morbidity. Diabetes is the most common cause of end-stage renal disease in the United States, and is primarily responsible for the 9% increase in prevalence of end-stage renal disease during the past 10 years. However, there is evidence that tight blood-pressure control can reduce the vascular complications of diabetes. This reduction was demonstrated in the United Kingdom Prospective Diabetes Study, in which patients who were randomized to a tight blood-pressure control group had 24% fewer vascular complications (including strokes and diabetic retinopathy) than patients in usual-care groups...
March 2000: Heart Disease
keyword
keyword
103222
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.